<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599792</url>
  </required_header>
  <id_info>
    <org_study_id>CP656.1002</org_study_id>
    <nct_id>NCT02599792</nct_id>
  </id_info>
  <brief_title>Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656</brief_title>
  <official_title>A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco® and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and
      multiple-ascending doses of CTP-656 dosed for 7 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This two-part study will assess in healthy male and female subjects a solid oral dose
      formulation of CTP-656 vs. Kalydeco® and the safety, tolerability and pharmacokinetic
      profiles of escalating CTP-656 solid oral doses following 7 days of dosing. In Part B, three
      doses of CTP-656 ranging from 75 mg up to 300 mg per day will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>7 days</time_frame>
    <description>adverse events categorized by body system and MedDRA term</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure exposure of test articles using area under the concentration time curve (AUC)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CTP-656, 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Oral Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kalydeco, 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-656, 75 mg or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 75 mg CTP-656 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-656, 150 mg or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 150 mg CTP-656 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-656, high dose or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered up to 300 mg CTP-656 for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-656</intervention_name>
    <arm_group_label>CTP-656, 150 mg</arm_group_label>
    <arm_group_label>CTP-656, 75 mg or matching placebo</arm_group_label>
    <arm_group_label>CTP-656, 150 mg or matching placebo</arm_group_label>
    <arm_group_label>CTP-656, high dose or matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for CTP-656</intervention_name>
    <arm_group_label>CTP-656, 75 mg or matching placebo</arm_group_label>
    <arm_group_label>CTP-656, 150 mg or matching placebo</arm_group_label>
    <arm_group_label>CTP-656, high dose or matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kalydeco</intervention_name>
    <arm_group_label>Kalydeco, 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults between 18 and 50 years of age, inclusive

          -  Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at
             screening

        Exclusion Criteria:

          -  History of clinically significant central nervous system (eg, seizures), cardiac,
             pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of
             Gilbert's syndrome or gastrointestinal (GI) conditions

          -  PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcF interval &gt; 450 msec obtained
             at screening visit or prior to the first dose of study drug

          -  Liver function tests greater than the upper limit of normal.

          -  Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
             virus surface antigen, or hepatitis C virus antibody at screening

          -  Urinalysis positive for greater than trace blood, protein or glucose

          -  A positive screen for alcohol, drugs of abuse, or tobacco use.

          -  Inability to comply with food and beverage restrictions during study participation.

          -  Donation or blood collection or acute loss of blood prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lana Pilja</last_name>
    <role>Study Director</role>
    <affiliation>Concert Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety and Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

